Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy
Source : https://onlinelibrary.wiley.com/doi/10.1111/bjh.17541
Bortezomib- and lenalidomide-based therapies have become standard front-line treatment for multiple myeloma (MM),1 resulting in many patients being refractory to bortezomib or lenalidomide at first relapse.2, 3 This may negatively...
Metabolic Changes Are Associated with Melphalan Resistance in Multiple Myeloma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34014671/
Multiple myeloma is an incurable hematological malignancy that impacts tens of thousands of people every year in the United States. Treatment for eligible patients involves induction, consolidation with stem cell...
Accidental Ixazomib Overdose in a Patient With Multiple Myeloma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/33980053/
Multiple myeloma is the second most common hematological malignancy. Ixazomib is the first oral proteasome inhibitor approved in the United States for the management of multiple myeloma who have received...
-
Mark Fesler5yrValuable piece as our best intended instructions don’t always “reach” the patient and while hopefully uncommon, this can be a resource for a practicing clinician
-
Multiple Myeloma Connect5yrPlease share your thoughts concerning overdose on oral chemotherapy.
Show More Comments
The Proximal Tubule Toxicity of Immunoglobulin Light Chains - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34013100/
Plasma and B cells dyscrasias that overproduce monoclonal immunoglobulin free light chains (FLCs) affect the kidney frequently in various ways. The hematologic dyscrasia responsible for the production of FLCs may...
Bilateral anterior cerebral artery occlusion following CD19- and BCMA-targeted chimeric antigen receptor T-cell therapy for a myeloma patient - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34009622/
Chimeric antigen receptor T (CAR-T)-cell therapy is a promising treatment for relapsed/refractory multiple myeloma (RRMM). In our previous report, CD19- and BCMA-targeted CAR-T co-administration was associated with a high response...